Abstract

Background: GLP-1 is a peptide hormone related to the glucagon superfamily and shares a significant amino acid sequence with glucagon. The glucagon superfamily peptides are secreted from the small intestine, pancreas, brain, and peripheral nerves. Furthermore, GLP-1 controls intestinal motility and decreases gastric motility. It also has an effect of satiety, which may be attributed to its effect on the gut, but it also has a direct effect on the hypothalamic feeding centers.

Aim: This study aims to assess the population awareness level regarding GLP-1 prescribing in PHCC in Abha City.

Methods: A descriptive cross-sectional web-based study was used. An online questionnaire was developed by the study researchers based on a literature review and after consultation of the field experts. The questionnaire of this study included participants’ demographic data, medical history, and GLP-1 use and satisfaction. Also, it covered participants’ awareness regarding GLP-1 and its effects.

Results: A total of 160 participants who used GLP-1 completed the study survey. Participants’ ages ranged from 18 to more than 50 years with a mean age of 34.8 ± 13.9 years old. Exactly 89 (55.6%) participants were females. The most used GLP-1 were Saxenda (39.4%), Ozempic (37.5%), and Trulicity (14.4%) while 8.8% used a combination of them. Exactly 127 (79.4%) participants had an overall poor awareness level regarding GLP-1 while only 33 (20.6%) had a good awareness level.

Conclusion: In conclusion, the current study revealed that a significant portion of diabetic and obese persons use GLP-1 for reducing weight and controlling blood glucose levels. On the other hand, their awareness level regarding the drugs was unsatisfactory.

Keywords: GLP-1, diabetes, obesity, awareness, use, population, knowledge, Saudi Arabia.